A scientific review on Chr. Hansen’s probiotic strain bifidobacterium, BB-12® has just been published in the peer-reviewed scientific journal "Microorganisms"
The review entitled "The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12®" provides a comprehensive insight into the characteristics and health benefits of the BB-12® probiotic strain. The paper encompasses key data on the BB-12® probiotic strain ― from taxonomy, strain characteristics and mechanisms, to clinical efficacy ― and it concludes that “BB-12® has well-established probiotic characteristics and proven beneficial health effects within gastrointestinal health and immune function.”
In terms of immune function, clinical studies have shown that the BB-12® probiotic strain increases the body’s resistance to common respiratory infections by interacting with the immune system. Furthermore, survival of the BB-12® probiotic strain through the gastrointestinal tract has been demonstrated and the BB-12® probiotic strain has been shown to support a healthy gastrointestinal microbiota.
The world’s most documented probiotic Bifidobacterium
“The BB-12® probiotic strain has been described in numerous scientific publications out of which more than 130 are publications of human clinical studies covering a variety of consumer groups from newborn preterm infants to elderly across various health areas. More than 200 publications are available via the Medline/PubMed publication database.
Other main probiotic bifidobacteria strains have less than 50 publications on the database. This makes Bifidobacterium animalis subsp. lactis (BB-12®) the world’s best documented probiotic Bifidobacterium,” explains Mikkel Jungersen MSc, Scientific Advisor, Scientific Affairs, Human Health & Nutrition.
All information in one document
“We expect our customers to warmly welcome the fact that all relevant information about the BB-12® probiotic strain is now compiled in one document”, says Lasse Nagell, Vice President, Global Sales & Marketing, Human Health & Nutrition.
“A lot of information is available on probiotics today. However the information varies a lot from strain to strain and from supplier to supplier so the reader may be left with a very fragmented picture. The review of the BB-12® probiotic strain is a valuable tool communicating clear facts and data about this specific strain,” Lasse Nagell concludes.
The review was published in Microorganisms (2014, 2(2), 92-110) in a Special Issue "Advances and New Perspectives in Microbial Research". The paper is open-access and can be read here: http://www.mdpi.com/2076-2607/2/2/92
The review, which is authored by Chr. Hansen scientists, finds that beneficial health effects of the BB-12® probiotic strain have been demonstrated through extensive clinical research. The BB-12® probiotic strain has been shown to improve bowel function, to have a protective effect against diarrhea, and to reduce side effects of antibiotic treatment.
Bifidobacterium, BB-12®: safety and origin
- Originates from Chr. Hansen’s collection of dairy cultures
- Identified as Bifidobacterium animalis subsp. lactis
- Used worldwide since 1985 with no reported adverse events
- Tested in clinical studies with no reported adverse events
- GRAS (Generally Recognized As Safe) notified by FDA
- QPS (Qualified Presumption of Safety) granted by EFSA
BB12® is a registered trademark of Chr. Hansen A/S.
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.